Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V116 in Pneumococcal Vaccine-naïve Adults 50 Years or Older
NCT05569954Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Solicited Injection-Site Adverse Events at 5 days, Percentage of Participants With Solicited Systemic Adverse Events at 5 days and 3 more. Started Nov 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05569954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569954.